These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. From serotonin receptor classification to the antimigraine drug sumatriptan. Saxena PR; Ferrari MD Cephalalgia; 1992 Aug; 12(4):187-96. PubMed ID: 1326401 [TBL] [Abstract][Full Text] [Related]
8. SUMATRIPTAN: a receptor-targeted treatment for migraine. Moskowitz MA; Cutrer FM Annu Rev Med; 1993; 44():145-54. PubMed ID: 8386498 [TBL] [Abstract][Full Text] [Related]
9. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Mitsikostas DD; Tfelt-Hansen P Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751 [TBL] [Abstract][Full Text] [Related]
10. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988 [TBL] [Abstract][Full Text] [Related]
11. Clinical effects and mechanism of action of sumatriptan in migraine. Ferrari MD; Saxena PR Clin Neurol Neurosurg; 1992; 94 Suppl():S73-7. PubMed ID: 1320526 [TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Peroutka SJ Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009 [TBL] [Abstract][Full Text] [Related]
13. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026 [TBL] [Abstract][Full Text] [Related]
14. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents. Peroutka SJ Pharmacol Rev; 1991 Dec; 43(4):579-86. PubMed ID: 1663621 [No Abstract] [Full Text] [Related]
15. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979 [TBL] [Abstract][Full Text] [Related]
16. Agonist activity of sumatriptan and metergoline at the human 5-HT1D beta receptor: further evidence for a role of the 5-HT1D receptor in the action of sumatriptan. Miller KJ; King A; Demchyshyn L; Niznik H; Teitler M Eur J Pharmacol; 1992 Sep; 227(1):99-102. PubMed ID: 1330643 [TBL] [Abstract][Full Text] [Related]
17. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Buzzi MG; Moskowitz MA; Peroutka SJ; Byun B Br J Pharmacol; 1991 Jun; 103(2):1421-8. PubMed ID: 1653072 [TBL] [Abstract][Full Text] [Related]
18. Preclinical studies on the anti-migraine drug, sumatriptan. Humphrey PP; Feniuk W; Marriott AS; Tanner RJ; Jackson MR; Tucker ML Eur Neurol; 1991; 31(5):282-90. PubMed ID: 1653134 [TBL] [Abstract][Full Text] [Related]
19. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor. Jansen I; Edvinsson L; Mortensen A; Olesen J Cephalalgia; 1992 Aug; 12(4):202-5. PubMed ID: 1326402 [TBL] [Abstract][Full Text] [Related]
20. Wolff Award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine1 receptor subtypes. Peroutka SJ; Havlik S; Oksenberg D Headache; 1993; 33(7):347-50. PubMed ID: 8397171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]